期刊
NATURE MEDICINE
卷 20, 期 5, 页码 552-558出版社
NATURE RESEARCH
DOI: 10.1038/nm.3519
关键词
-
资金
- US Department of Defense
- US National Institutes of Health Director's New Innovator Award Program [1-DP2-CA186569]
- Ludwig Institute for Cancer Research
- Radiological Society of North America [RR1221]
- Association of American Cancer Institutes Translational Cancer Research Fellowship
- Siebel Stem Cell Institute
- Thomas and Stacey Siebel Foundation
- Doris Duke Clinical Scientist Development Awards
Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of cancer burden, but existing ctDNA detection methods have insufficient sensitivity or patient coverage for broad clinical applicability. Here we introduce cancer personalized profiling by deep sequencing (CAPP-Seq), an economical and ultrasensitive method for quantifying ctDNA. We implemented CAPP-Seq for non-small-cell lung cancer (NSCLC) with a design covering multiple classes of somatic alterations that identified mutations in >95% of tumors. We detected ctDNA in 100% of patients with stage II-IV NSCLC and in 50% of patients with stage I, with 96% specificity for mutant allele fractions down to similar to 0.02%. Levels of ctDNA were highly correlated with tumor volume and distinguished between residual disease and treatment-related imaging changes, and measurement of ctDNA levels allowed for earlier response assessment than radiographic approaches. Finally, we evaluated biopsy-free tumor screening and genotyping with CAPP-Seq. We envision that CAPP-Seq could be routinely applied clinically to detect and monitor diverse malignancies, thus facilitating personalized cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据